Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer

Journal of Surgical Oncology

Volumn 104, Issue 1, 2011, Pages 29-36

  Yin, Mingzhu ^a   Li, Cong ^a   Li, Xia ^a   Lou, Ge ^a   Miao, Bing ^b   Liu, Xiaodong ^a   Meng, Fanling ^a   Zhang, Haiyu ^a   Chen, Xiuwei ^a   Sun, Meng ^a   Ling, Qiu ^a   Zhou, Rouli ^c  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Senior Officials Inpatient Ward   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Chemotherapy resistance; Epithelial ovarian carcinoma; LAPTM4B; Survival

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; PACLITAXEL;

ARTICLE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYSOSOME ASSOCIATED PROTEIN TRANSMEMBRANE 4 BETA GENE; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79958122921     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21912     Document Type: Article

References (18)

1. Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30. (Pubitemid 40310185)
2. Kolwijck E, Lybol C, Bulten J, et al.: Prevalence of cysts in epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2010;151:96-100.
3. Chung HH, Hwang SY, Jung KW, et al.: Ovarian cancer incidence and survival in Korea: 1993-2002. Int J Gynecol Cancer 2007;17:595-600. (Pubitemid 46743997)
4. Liu XR, Zhou RL, Zhang QY, et al.: Structure analysis and expressions of a novel tetratransmembrane protein, lysosoma - associated protein transmembrane 4 beta associated with hepatocellular carcinoma. World J Gastroenterol 2004;10:1555-1559.
5. Shao GZ, Zhou RL, Zhang QY, et al.: Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 2003;22:5060-5069.
6. Liu JJ, Zhou RL, Zhang N, et al.: Biological function of a novel gene over expressed in human hepatocellular carcinoma. Chin Med J 2000;113:881-885.
7. Kasper G, Vogel A, Klaman I, et al.: The human LAPTM4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression. Cancer Lett 2005;224:93-103. (Pubitemid 40720370)
8. Yang Y, Yang H, McNutt MA, et al.: LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep 2008;20:1077-1083.
9. Meng F, Yin M, Song H, et al.: LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma. Int J Gynecol Cancer 2010;20:745-750.
10. Yin M, Xu Y, Lou G, et al.: LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis. Int J Cancer 2010. DOI: 10.1002/ijc.25689.
11. Zhou L, Zhou L, He XD, et al.: Overexpression of LAPTM4B- 35 closely correlated with clinicopathological features and postresectional survival of gallbladder carcinoma. Eur J Cancer 2007;4:809-815. (Pubitemid 46502911)
12. Robert J, Morgan JR, Ronald D, et al.: Ovarian cancer including Fallopian tube cancer and Primary peritoneal cancer. NCCN clinical practice guidelines in oncology. v.2. 2009.
13. Peng C, Zhou RL, Shao GZ, et al.: Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma. World Gastroenterol 2005;11:2704-2708. (Pubitemid 40704233)
14. Li Z, He X-D, Cui Q-C, et al.: LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 2010;136:275-281.
15. Yang H, Xiong F, Qi R, et al.: LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma. J Surg Oncol 2010;101:363-369.
16. Zhou L, He XD, Cui QC, et al.: Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett 2008;2:209-217.
17. Ferrandina G, Ranelletti FO, Martinelli E, et al.: Cyclo-oxygenase- 2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer. BMC Cancer 2006;6:182.
18. Li Y, Zou L, Li Q, et al.: Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 2010;16:214-218.